WallStSmart

Lineage, Inc. Common Stock (LINE)vsUcommune International Ltd (UK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 20402% more annual revenue ($5.36B vs $26.12M). LINE leads profitability with a -1.9% profit margin vs -144.9%. LINE earns a higher WallStSmart Score of 36/100 (F).

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: 0.81

UK

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 3.0
Piotroski: 3/9Altman Z: -20.17
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LINEUndervalued (+75.9%)

Margin of Safety

+75.9%

Fair Value

$161.49

Current Price

$35.99

$125.50 discount

UndervaluedFair: $161.49Overvalued

Intrinsic value data unavailable for UK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

UK1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Areas to Watch

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

UK4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.95M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.043/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : UK

The strongest argument for UK centers on Price/Book.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Bear Case : UK

The primary concerns for UK are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

LINE is growing revenue faster at -0.2% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LINE scores higher overall (36/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.

Visit Website →

Ucommune International Ltd

REAL ESTATE · REAL ESTATE SERVICES · China

Ucommune International Ltd provides and manages agile office spaces in China and internationally. The company is headquartered in Beijing, China.

Want to dig deeper into these stocks?